Compare ResMed Inc. (RMD) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Thomson Reuters Corp — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Thomson Reuters Corp trades at $101.96 (market cap $43.89B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Thomson Reuters Corp for 63 Days on average.
| RMD | TRI | |
|---|---|---|
Market Cap | $31.89B | $43.89B |
Volume | 618,314 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $277.88 | $163.45 |
52-Week Low | $182.82 | $76.55 |
Typical Hold Time | 51 Days | 63 Days |
Enterprise Value | $31.24B | $46.51B |
Dividend Yield | 1.16% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Thomson Reuters (TRI) trades at $99.28, up 1.21% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its print unit to focus on technology offerings and launching its proprietary AI model, positioning for future growth.
TRI presents a compelling investment case with analyst consensus targeting $133.25 (34% upside) and strong institutional support. However, risks include recent cybersecurity incidents and margin compression from 2023 peaks. The company's shift toward AI and recurring revenue models supports long-term growth potential despite near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
